Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy
about
Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's diseaseDeconvoluting the complexity of autophagy and Parkinson's disease for potential therapeutic purposeGenetically engineered mouse models of Parkinson's diseasePathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body diseaseAutophagy and neurodegenerationRole of neurotrophic factor alterations in the neurodegenerative process in HIV associated neurocognitive disordersProtein degradation pathways in Parkinson's disease: curse or blessingHuman A53T α-synuclein causes reversible deficits in mitochondrial function and dynamics in primary mouse cortical neuronsMechanisms of HIV-1 Tat neurotoxicity via CDK5 translocation and hyper-activation: role in HIV-associated neurocognitive disordersGenetic and chemical activation of TFEB mediates clearance of aggregated α-synucleinOverexpression of the autophagic beclin-1 protein clears mutant ataxin-3 and alleviates Machado-Joseph diseasePassive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body diseaseTime course and progression of wild type α-synuclein accumulation in a transgenic mouse model.Microglial beclin 1 regulates retromer trafficking and phagocytosis and is impaired in Alzheimer's disease.Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.ESCRT-mediated uptake and degradation of brain-targeted α-synuclein single chain antibody attenuates neuronal degeneration in vivo.Rapamycin improves motor function, reduces 4-hydroxynonenal adducted protein in brain, and attenuates synaptic injury in a mouse model of synucleinopathyRegulation of amyloid precursor protein processing by the Beclin 1 complexMolecular chaperones and protein folding as therapeutic targets in Parkinson's disease and other synucleinopathiesRapamycin is neuroprotective in a rat chronic hypertensive glaucoma model.Stem cell models of Alzheimer's disease: progress and challenges.Parkinson's disease-implicated kinases in the brain; insights into disease pathogenesis.Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein.Novel AAV-based rat model of forebrain synucleinopathy shows extensive pathologies and progressive loss of cholinergic interneuronsReducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models.Autophagy in neurodegenerative disorders: pathogenic roles and therapeutic implicationsPathogenic role of BECN1/Beclin 1 in the development of amyotrophic lateral sclerosis.HIV life cycle, innate immunity and autophagy in the central nervous systemp62/SQSTM1-dependent autophagy of Lewy body-like α-synuclein inclusionsMacroautophagy abnormality in essential tremor.Taking aim at Alzheimer's disease through the mammalian target of rapamycinDepletion of Beclin-1 due to proteolytic cleavage by caspases in the Alzheimer's disease brainNeuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders.The many faces of α-synuclein: from structure and toxicity to therapeutic target.Autophagy failure in Alzheimer's disease--locating the primary defect.Identification of the sites of tau hyperphosphorylation and activation of tau kinases in synucleinopathies and Alzheimer's diseases.NURR1 in Parkinson disease--from pathogenesis to therapeutic potential.HIV-1 Tat alters neuronal autophagy by modulating autophagosome fusion to the lysosome: implications for HIV-associated neurocognitive disorders.Environmental neurotoxic challenge of conditional alpha-synuclein transgenic mice predicts a dopaminergic olfactory-striatal interplay in early PD.Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy
P2860
Q24324577-0E2A663F-8567-4B62-82C6-7CDE8CAFEAB4Q26785491-31FEFFB3-125D-411C-92DB-79F92C29CB0EQ26852964-98B2A8A0-5C68-4591-9795-545DFA70CFB0Q26853610-A118909B-92EF-486F-BC86-7DBD9EF13CE7Q26991692-EE902452-2E39-4E8B-93F9-7094DD8FFFCDQ27025573-5CB3EECD-1B33-48B1-846A-2A7C8DC12913Q27026029-48B36F57-BFE3-429F-9BD9-7C4C9C1CD8FDQ27332460-5DAEEB32-57A1-4430-B9D7-52CC908121DFQ28082139-A4310891-FA70-447C-8E28-D3198F38F50FQ28544679-C2F6DABE-5DDF-43C2-808D-4620E5434B3FQ28568604-8ABF0C70-486A-4BB3-AF90-96D7D5331F29Q28740551-2BAB56BE-5E3A-444E-9B9F-8B85120B0F55Q30532478-415AB93E-698F-4100-AC08-66E7A2E18438Q30545790-DEDA7908-8D11-4E69-AA06-822D6B053872Q30578913-CEB925C8-356B-4D9A-A35D-4303D7FC33A0Q30650119-B1A856AF-CDF3-4736-8ED4-08557751A110Q30662442-94C85783-D9C4-431C-9F65-985312B44E77Q33608732-39284A01-FD67-419A-B256-4A8C4A4939BAQ33715640-3FCB29E3-F260-41E0-B7CD-18860492211AQ33748844-B8284364-FD9F-4263-830F-30207B2E7B23Q33796378-A2FFF007-1B6B-4F02-BD6D-200FFFAE1472Q33797449-E6AAA5CF-7D27-477D-AF44-D0FF0D476481Q33847712-F8CD7402-223C-4DD2-AC0E-901AC222FB5AQ33856698-87926038-69D9-4A63-8B51-9ACF1A8B4190Q33865366-BB0F8EBE-1B4B-4250-9F2E-D381A9447BB8Q34311607-7AA18005-C22D-4EC2-961E-E3FBE8E9CF1FQ34373108-8F953687-020F-46B3-AC9F-AC5F97A27F80Q34420382-0ECF5A62-7E07-4025-A989-19E4708B7744Q34541317-8EDF740D-2601-4CAE-8C61-82DCAE42FEC9Q34541604-4DB2A5B1-A470-4D26-80FB-CF879ED5F884Q34603651-C5541194-4270-40D9-B730-5EA2FABD9E64Q34733374-8CFDF98A-00C1-45DA-8E53-1E660CC2489AQ34914245-0890B8C8-143D-4065-82FF-F84D644F6080Q34972009-9FDAF8D1-09AA-4EC5-A596-E8A88244D45AQ34987827-EC9FE164-2FE1-48F9-BD4B-E9E0D4BA4115Q35000764-85B05B60-AE20-4245-A111-6FCACDDC9E6EQ35017493-670527F3-5319-4407-85AE-2D974A7E1F25Q35044780-F2A6BE9B-06E5-4396-A998-D658F8DF6262Q35073958-BBE36191-0203-471D-ABB2-15F48DD75193Q35544737-FECF4578-E2C6-4D43-A026-1FFA69B75044
P2860
Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Selective molecular alteration ...... odels of alpha-synucleinopathy
@ast
Selective molecular alteration ...... odels of alpha-synucleinopathy
@en
type
label
Selective molecular alteration ...... odels of alpha-synucleinopathy
@ast
Selective molecular alteration ...... odels of alpha-synucleinopathy
@en
prefLabel
Selective molecular alteration ...... odels of alpha-synucleinopathy
@ast
Selective molecular alteration ...... odels of alpha-synucleinopathy
@en
P2093
P2860
P50
P1433
P1476
Selective molecular alteration ...... odels of alpha-synucleinopathy
@en
P2093
Amy Paulino
Anthony Adame
Brian Spencer
Christina Patrick
Douglas Galasko
Lawrence Hansen
P2860
P356
10.1371/JOURNAL.PONE.0009313
P407
P577
2010-02-19T00:00:00Z